Rani Therapeutics Holdings (RANI) Operating Leases (2022 - 2026)

Rani Therapeutics Holdings' Operating Leases history runs 5 years deep, the most recent figure standing at $2.5 million for Q1 2026.

• On a quarterly basis, Operating Leases fell 27.52% year-over-year to $2.5 million in Q1 2026; TTM through Mar 2026 was $2.5 million, a 27.52% decrease from a year earlier, with the FY2025 full-year figure at $2.7 million, down 24.88% from the prior year.
• Operating Leases eased to $2.5 million in Q1 2026 per RANI's latest filing, from $2.7 million in the prior quarter.
• Across five years, Operating Leases topped out at $4.7 million in Q1 2024 and bottomed at $59000.0 in Q4 2022.
• The 5-year median for Operating Leases is $2.6 million (2025), against an average of $2.1 million.
• Across the five-year window, Operating Leases tumbled 46.23% in 2023 and surged 2249.12% in 2024, its largest moves.
• Year by year, Operating Leases stood at $59000.0 in 2022, then soared by 189.83% to $171000.0 in 2023, then jumped by 2026.9% to $3.6 million in 2024, then slipped by 24.88% to $2.7 million in 2025, then declined by 9.19% to $2.5 million in 2026.
• Per Business Quant, the three latest RANI Operating Leases figures stand at $2.5 million (Q1 2026), $2.7 million (Q4 2025), and $3.0 million (Q3 2025).